Skip to main content.

The University of Kansas Medical Center's Division of Medical Oncology and Division of Hematologic Malignancy and Cellular Therapeutics (HMCT) offers a three-year combined fellowship program accredited through the Accreditation Council for Graduate Medical Education. This program, when completed successfully, provides board eligibility in both hematology and medical oncology.

The university is affiliated with the Kansas City Veterans Affairs Medical Center. Fellows spend one-fourth to one-third of their time at the Kansas City VA during the fellowship program.

The fellowship program encompasses activities in both the outpatient and inpatient settings. Emphasis is placed on the current practice of the specialty with outpatient care and continuity of care in an interactive multidisciplinary environment. Fellows are placed in specialty-driven continuity clinics that allow them to follow and manage patients prospectively to foster independence and a sense of patient ownership. In addition, they will rotate through other specialty clinics of hematology and oncology that are led by a group of nationally recognized physicians who practice cutting-edge medicine with a strong focus on clinical trials and multidisciplinary care.

Fellows will gain hands-on exposure to one of the nation's largest stem cell transplant and cellular therapeutics programs. Another key strength of our program is our nationally-recognized Breast Cancer Prevention Program, a sophisticated early-phase clinical research program for drug development trials, and the robust basic and translational research tracks.

All fellows receive one-on-one academic mentorship with the expectation of fruitful scholarly activities and at least two manuscripts or national presentations during their 3rd-year fellowship.

The fellowship is part of The University of Kansas Cancer Center's National Cancer Institute Designated Cancer Center (NCICC) and is consistently ranked by The U.S. News and World Report among the nation's top programs.

Fellows are expected to pick one of the three tracks in fellowship: clinical track, clinical research track, or basic/translational research track) by mid-year of their first year of training. Fellows are expected to participate and contribute significant time in research such as writing clinical trial protocols with faculty mentors. If prior experience or interest matches with the translational or basic research program, there will be an opportunity to spend up to 18 months in an appropriate basic or correlative research lab. The clinical research track will have a block of time in the phase I clinical research program to learn about early-phase trial development and patient enrollment in early phase trials. A portion of time is spent on electives, which include radiation therapy, blood banking, and palliative care. We are a member and participant of some of the large national cooperative clinical trials groups, Southwest Oncology Group (SWOG), ASBMT, MPN-RC, and NRG Oncology. Our faculty research interests are diversified. These research interests include clinical research (Phase II and Phase III program), Phase I research program, translational and basic research in various fields as well as cancer prevention research. If there is more interest in our research program for fellowship training, please contact the program director for further details.

Prakash Neupane, M.D.
Professor of Medicine
Director, Hematology Oncology Fellowship Program

Heather Male, M.D.
Associate Professor of Medicine
Director, Inpatient HMCT
Associate Director, Hematology Oncology Fellowship Program

Internal Medicine

University of Kansas Medical Center
Internal Medicine
Medical Oncology Division
Mailstop 1022
3901 Rainbow Boulevard
Kansas City, KS 66160
Administrative Office: 913-588-6029
Fellowship: 913-588-0348